MedElevator
Войти в исследования BRAF mutations in hairy-cell leukemia.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tiacci Enrico, Trifonov Vladimir, Schiavoni Gianluca, Holmes Antony, Kern Wolfgang, Martelli Maria Paola, Pucciarini Alessandra, Bigerna Barbara, Pacini Roberta, Wells Victoria A, Sportoletti Paolo, Pettirossi Valentina, Mannucci Roberta, Elliott Oliver, Liso Arcangelo, Ambrosetti Achille, Pulsoni Alessandro, Forconi Francesco, Trentin Livio, Semenzato Gianpietro, Inghirami Giorgio, Capponi Monia, Di Raimondo Francesco, Patti Caterina, Arcaini Luca, Musto Pellegrino, Pileri Stefano, Haferlach Claudia, Schnittger Susanne, Pizzolo Giovanni, Foà Robin, Farinelli Laurent, Haferlach Torsten, Pasqualucci Laura, Rabadan Raul, Falini Brunangelo
Аннотация
METHODS: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL.
RESULTS: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. CONCLUSIONS; The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.).